US · AXGN
AxoGen, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Alachua, FL 32615
- Website
- axogeninc.com
Price · as of 2025-12-31
$43.28
Market cap 1.59B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $49.79 | +15.04% |
| Intrinsic Value(DCF) | $23.29 | -46.19% |
| Graham-Dodd Method(GD) | $1.09 | -97.47% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $2.90 | $510.98 | $57.18 | $0.00 | $0.00 |
| 2012 | $3.99 | $29.60 | $38.34 | $0.00 | $0.00 |
| 2013 | $3.65 | $25.99 | $1,422.32 | $0.00 | $0.00 |
| 2014 | $3.25 | $30.38 | $262.89 | $0.00 | $0.00 |
| 2015 | $5.14 | $33.11 | $1,006.98 | $0.00 | $0.00 |
| 2016 | $10.05 | $36.15 | $924.54 | $0.00 | $0.00 |
| 2017 | $35.35 | $47.06 | $436.00 | $0.00 | $0.00 |
| 2018 | $19.18 | $32.55 | $135.36 | $0.94 | $0.00 |
| 2019 | $11.95 | $30.91 | $38.72 | $0.00 | $0.00 |
| 2020 | $20.51 | $39.50 | $0.97 | $0.11 | $0.00 |
| 2021 | $8.32 | $25.73 | $0.17 | $0.00 | $0.00 |
| 2022 | $7.58 | $25.50 | $0.00 | $0.00 | $0.00 |
| 2023 | $8.75 | $36.45 | $0.00 | $0.00 | $0.00 |
| 2024 | $17.73 | $75.19 | $5.36 | $1.22 | $0.00 |
| 2025 | $30.65 | $49.79 | $4.54 | $1.09 | $0.00 |
AI valuation
Our deep-learning model estimates AxoGen, Inc.'s (AXGN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $49.79
- Current price
- $43.28
- AI upside
- +15.04%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$23.29
-46.19% upside
Graham-Dodd
$1.09
-97.47% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AXGN | AxoGen, Inc. | $43.28 | 1.59B | +15% | -46% | -97% | — | -89.88 | 10.95 | 6.27 | 7266.33 | -187.94 | 11.56 | 74.31% | -3.49% | -6.97% | -13.49% | -6.24% | -7.38% | 0.15 | -1.02 | 5.11 | 2.62 | -84.93 | 4783.00% | 2021.00% | -2676364.00% | -0.21% | 0.03 | -2.33% | 0.00% | 0.00% | 4.07% | -177.75 | -475.67 | 6.19 | 8.61 |
| AHCO | AdaptHealth Corp. | $9.15 | 1.24B | +239% | -53% | — | — | -19.73 | 0.86 | 0.40 | 2.75 | — | -1.18 | 17.52% | 5.74% | -2.18% | -4.27% | 7.18% | -1.50% | 0.12 | 1.76 | 1.02 | 0.67 | 0.16 | -18525.00% | -49.00% | -696.00% | 16.84% | 0.84 | 8.45% | 0.00% | 0.00% | 148.90% | 7.43 | 6.31 | 0.43 | 0.97 |
| CTEV | Claritev Corporation | $13.47 | 222.6M | +1,151% | -57% | — | — | -0.83 | -1.36 | 0.25 | 10.21 | — | -0.05 | 27.61% | 4.67% | -29.45% | 632.60% | 0.76% | -5.66% | -26.64 | 0.11 | 0.86 | 0.59 | 9.71 | -8303.00% | 374.00% | 1685.00% | -5.18% | 0.45 | -0.27% | 0.00% | 0.00% | 0.00% | 107.70 | -395.26 | 5.03 | -0.45 |
| IART | Integra LifeSciences Hold… | $11.38 | 886.41M | +457% | -63% | — | — | -1.55 | 0.77 | 0.49 | -1.58 | -0.02 | -1.13 | 51.69% | -30.17% | -31.58% | -39.90% | -21.27% | -13.52% | 0.21 | -5.72 | 2.54 | 1.19 | 0.04 | 736120.00% | 153.00% | -22439.00% | -3.88% | 0.11 | -1.46% | 0.00% | 0.00% | 219.53% | -1.53 | -24.24 | 0.46 | 0.59 |
| INMD | InMode Ltd. | $13.75 | 871.18M | +312% | -24% | +30% | -77% | 9.40 | 1.29 | 2.38 | 3.06 | — | 1.29 | 78.54% | 23.05% | 25.33% | 13.53% | 56.67% | 12.09% | 0.02 | — | 9.88 | 8.55 | -2.61 | -3644.00% | -616.00% | -3615.00% | 9.56% | 1.21 | 65.78% | 0.00% | 0.00% | 30.54% | 3.98 | 4.03 | 0.92 | 9.96 |
| IRMD | IRadimed Corporation | $103.53 | 1.32B | -46% | -36% | — | -72% | 33.89 | 7.51 | 8.90 | 26.33 | 305.02 | 7.79 | 76.94% | 29.99% | 26.26% | 24.31% | 59.56% | 20.20% | 0.00 | — | 8.84 | 7.38 | -2.29 | 1111.00% | 1171.00% | 22283.00% | 2.70% | 3.01 | 60.30% | 2.10% | 71.10% | 2.77% | 27.31 | 34.04 | 8.19 | 37.09 |
| LFMD | LifeMD, Inc. | $2.67 | 128.52M | +1,008% | +2,300% | — | — | -10.27 | -35.07 | 0.91 | -27.43 | — | -9.02 | 88.67% | -7.60% | -8.89% | 1891.64% | 123.73% | -28.61% | -4.58 | -7.40 | 0.81 | 0.72 | 1.49 | -2429.00% | 3927.00% | 677408.00% | 3.11% | 0.29 | -45.81% | 1.61% | -16.60% | 1.61% | -11.30 | 30.53 | 0.86 | -1.05 |
| OPK | OPKO Health, Inc. | $1.20 | 921.24M | +2,047% | -57% | — | +48% | -4.21 | 0.75 | 1.56 | -20.44 | -1.44 | 3.55 | 61.01% | -36.08% | -37.20% | -17.14% | -14.89% | -10.92% | 0.33 | -2.16 | 3.97 | 3.13 | -0.89 | 29113.00% | -1490.00% | -848.00% | -20.10% | -1.22 | -13.88% | 0.00% | 0.00% | 3.09% | -4.53 | -5.20 | 1.64 | -0.35 |
| SANA | Sana Biotechnology, Inc. | $4.21 | 1.12B | — | — | — | — | -2.23 | 2.38 | — | -2.10 | — | 11.75 | 0.00% | — | — | -99.17% | -144.07% | -50.03% | 0.38 | — | 3.54 | 3.36 | 0.13 | -2055.00% | — | -622.00% | -43.07% | -4.91 | -135.54% | 0.00% | 0.00% | 0.66% | -1.97 | -2.09 | — | -4.58 |
| TNDM | Tandem Diabetes Care, Inc… | $25.30 | 1.72B | +78% | -60% | — | — | -8.29 | 10.94 | 1.67 | -10.59 | -7.76 | 10.94 | 52.31% | -7.70% | -20.17% | -97.88% | -25.81% | -22.15% | 2.86 | -9.88 | 2.55 | 1.89 | -2.03 | 10680.00% | 793.00% | -69409.00% | -1.75% | -0.04 | -9.80% | 0.00% | 0.00% | 2.97% | -23.67 | -62.33 | 1.82 | 0.78 |
| TSHA | Taysha Gene Therapies, In… | $4.53 | 1.24B | +543% | -85% | — | +183% | -4.90 | 6.12 | 52.53 | -4.11 | — | 6.12 | 100.00% | -1097.55% | -1071.62% | -121.94% | 1496.02% | -53.62% | 0.88 | -896.66 | 5.42 | 5.30 | 0.86 | -6284.00% | -4607.00% | 151.00% | -18.64% | -3.10 | 1334.73% | 0.00% | 0.00% | 0.00% | -3.96 | -4.43 | 43.43 | -3.26 |
About AxoGen, Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
- CEO
- Michael D. Dale
- Employees
- 451
- Beta
- 0.96
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($23.29 ÷ $43.28) − 1 = -46.19% (DCF, example).